HeartBeam Device Shows Higher Specificity Than Standard ECG in Heart Attack Pilot Study

PUBT · 1d ago
HeartBeam Device Shows Higher Specificity Than Standard ECG in Heart Attack Pilot Study
  • HeartBeam announced positive results from its 132-patient ALIGN-ACS pilot study, presented at the TCT 2026 conference in San Diego.
  • Patient-recorded ECGs produced fewer false positives than standard 12-lead ECGs, with comparable ability to detect acute coronary syndrome.
  • Cardiologists interpreted device recordings more consistently; all patients successfully recorded their own ECGs under clinical supervision without prior training.
  • The findings will inform a U.S. pivotal study planned for the first quarter of 2027 to support an expanded FDA indication.
  • The system is not currently FDA-cleared for heart attack assessment; that use remains investigational.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261102249982) on November 02, 2026, and is solely responsible for the information contained therein.